CooperVision to Introduce MyDay® MiSight® 1-Day Lenses for Myopia Control

CooperVision Set to Launch Innovative MyDay® MiSight® 1-Day Lenses

CooperVision has officially announced an exciting new product that aims to address the growing myopia epidemic among children. The company will soon introduce its MyDay® MiSight® 1-day soft contact lenses in selected European markets, including the UK. These innovative lenses are designed specifically for myopia control, combining a proven technology called ActivControl® with advanced silicone hydrogel material found in MyDay® lenses.

The Growing Concern of Myopia

Predictions indicate that one in two children born today may develop myopia by the age of 20. Myopia not only impacts daily activities such as school and sports but also has a significant negative effect on overall quality of life. Rapid progression of myopia can occur, particularly during early childhood, making early intervention crucial for managing this condition effectively.

Debbie Olive, CooperVision’s Commercial Director, reaffirmed the company's commitment to combating myopia, saying, "Our dedication to addressing myopia, both scientifically and commercially, remains resolute. With MyDay® MiSight® 1-day, we are maximizing the potential to transform myopia control for children." Recent studies demonstrate that the ActivControl® technology integrated into these lenses has been effective in reducing the progression of myopia by nearly 50%. This claim is backed by the longest clinical trials concerning soft contact lenses for children, which show the positive results of this innovative approach.

Advancements in Eye Care Technology

The MyDay® MiSight® 1-day lenses are designed to offer both corrective vision zones and treatment zones within the same lens. This dual function not only assists in providing clarity but also plays a significant role in controlling the worsening of myopia. The technology allows for a seamless transition for children as they move towards adult contact lens use, thanks to shared specifications and materials with the MyDay® series.

Jennifer Lambert, Vice President of Myopia Management and Corneal Health at CooperVision, elaborates on the benefits: "This innovation ensures that myopia control is consistently available, benefiting children throughout the day simply by wearing their contact lenses. We aim to set a new standard in the management of myopia for young wearers."

Launch Details and Availability

The MyDay® MiSight® lenses will be available in the UK and select European markets with a variety of power parameters:

- Sphere power range: -0.25 to -6.00 D (0.25 D steps) and -6.50 to -10.00 D (0.50 D steps).

For further insights on this groundbreaking launch and CooperVision's evidence-based myopia management portfolio, interested parties can visit their UK website.

About CooperVision

CooperVision, a division of CooperCompanies (Nasdaq: COO), stands as a leading name in the global contact lens manufacturing landscape. They offer a vast range of daily, biweekly, and monthly disposable contact lenses manufactured from advanced optical materials, catering to diverse vision correction needs, including myopia, astigmatism, and presbyopia.

With a commitment to innovation and excellence, CooperVision not only provides products that enhance vision but also strives to improve lives globally. The company operates in over 130 countries and positively impacts millions of lives annually. To learn more, visit CooperVision’s website.

In summary, the anticipated launch of MyDay® MiSight® 1-day lenses is a significant step forward in the fight against myopia, ensuring that children across Europe will have access to effective, comfortable vision correction options that help manage their sight as they grow.